A recent study reveals that patients who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who stop traditional lifestyle programs.
Findings released in a prominent medical journal demonstrates that while overweight individuals can lose about a fifth of their total mass while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month once they quit.
"People buying such drugs should be aware of the danger of rapid weight regain when the treatment concludes," stated expert Dr. Susan Jebb.
Such speed of regain implies a reversion to starting mass within about one and a half years.
Comparing Therapies
The analysis, which looked at 37 of studies involving over 9,000 of patients, compared the outcomes of the injectable medications with conventional dieting.
The team note that individuals who lose weight through lifestyle changes alone generally have a slower weight regain—approximately 0.1 kg a month—post-intervention.
Explaining the Rapid Rebound
Doctors suggest the mode of action of the jabs explains the accelerated regain.
GLP-1 drugs imitate a body's own chemical called GLP-1, which moderates appetite.
"Long-term administration of GLP-1 levels far above than the body's typical production might result in the system to produce less of its own natural GLP-1, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication means hunger is no longer kept in check, making overeating much more probable."
A Lifelong Disease?
The NHS recommend the injections for individuals with obesity-related health risks, accompanied by recommended lifestyle changes.
A number of clinicians argue that, considering the significant potential of weight regain, the therapy is often long-term.
This view is supported by drug manufacturers, who note that the findings "highlight the chronic nature of obesity," comparing it to managing conditions like hypertension.
User Accounts
Users who have stopped the jabs report a intense return of cravings.
"I experienced a trigger that goes on and I was suddenly ravenous," described one woman.
This difficulty is exacerbated if patients have not adopted lasting dietary or behavioural changes during therapy.
Widespread Interest
Recent estimates suggest that a significant number of people in the UK have used these injections in the last 12 months, with interest remaining high.
- Adoption is more common among females than males.
- The middle-aged demographic shows the greatest usage rates.
- Many access the drugs through private healthcare rather than the NHS.
In conclusion, researchers emphasize that while the jabs are powerful agents for shedding pounds, they are not a magic solution and long-term success likely depends on combined behavioural support.
